CV Therapeutics' Ranexa is expected to fall well short of Wall Street expectations. Given the growing popularity of invasive angina techniques and the drug's relatively unimpressive trial results, CV Therapeutics' Ranexa looks set to disappoint Wall Street expectations. Datamonitor forecasts Ranexa to generate US revenues of around $20 million in 2006, rising to $163 million by 2009, well below Wall Street consensus of $33 million and $313 million, respectively. Pharmaceutical Business Review (http://www.pharmaceutical-business-review.com/article_feature.asp?guid=C05FBF43-187F-4529-B66D-9F738844B3EF)